Oncology History Main Article

Daiichi Sankyo Cancer Enterprise Milestones

Oncology History

  • 2018
    December 2018

    Daiichi Sankyo and Puma Biotechnology enter into a preclinical research collaboration with Memorial Sloan Kettering Cancer Center (MSK) to explore the combination of Daiichi Sankyo’s investigational antibody drug conjugate DS-8201 and Puma Biotechnology’s irreversible pan-HER inhibitor neratinib in HER2-mutated or HER2-positive solid tumors.

  • November 2017

    Pivotal phase 2 DESTINY-Gastric01 study evaluating the safety and efficacy of DS-8201, an investigational HER2-targeting antibody drug conjugate (ADC), in patients with HER2-positive advanced gastric or gastroesophageal junction adenocarcinoma resistant or refractory to trastuzumab was initiated in Japan and South Korea

  • 2017
    October 2017

    Pivotal phase 3 placebo-controlled ENLIVEN study of pexidartinib met its primary endpoint of tumor response as measured by tumor size reduction in patients with symptomatic tenosynovial giant cell tumor (TGCT) where surgical resection is potentially associated with worsening functional limitation or severe morbidity

  • October 2017

    Daiichi Sankyo enters into an option agreement with Glycotope GmbH for future strategic collaboration and licensing to develop an ADC by combining Daiichi Sankyo’s proprietary ADC technology with Glycotope’s investigational tumor-associated TA-MUC1 antibody PankoMab-GEX®

  • 2017
    September 2017

    Daiichi Sankyo and The University of Texas MD Anderson Cancer Center enter into a multi-year collaboration focused on accelerating the development of novel therapies for acute myeloid leukemia (AML)

  • August 2017

    Pivotal phase 2 DESTINY-Breast01 evaluating the safety and efficacy of DS-8201 in patients with HER2-positive unresectable and/or metastatic breast cancer who are resistant or refractory to ado-trastuzumab emtansine (T-DM1) was initiated

  • 2017
    August 2017

    DS-8201 granted Breakthrough Therapy Designation for the treatment of patients with HER2-positive, locally advanced or metastatic breast cancer who have been treated with trastuzumab and pertuzumab and have disease progression after ado-trastuzumab emtansine (T-DM1)

  • August 2017

    Daiichi Sankyo enters into a worldwide licensing agreement for Daiichi Sankyo’s novel RET inhibitor, DS-5010. Under the terms of the agreement, Daiichi Sankyo grants Boston Pharmaceuticals worldwide rights for the research, development, manufacturing and commercialization of DS-5010

  • 2017
    August 2017

    Daiichi Sankyo and Bristol-Myers Squibb announced a collaborative clinical trial to evaluate the combination of Bristol-Myers Squibb’s immunotherapy Opdivo (nivolumab) and Daiichi Sankyo’s investigational antibody drug conjugate DS-8201 in HER2-expressing metastatic breast and urothelial (bladder) cancers

  • July 2017

    Daiichi Sankyo signs an agreement with Max Planck Innovation GmbH and the Lead Discovery Center GmbH providing Daiichi Sankyo with the option to receive the exclusive rights to a new lead compound for the treatment of cancer to be discovered and developed at the Lead Discovery Center

  • 2017
    April 2017

    Daiichi Sankyo announced an initial 15 billion yen investment to optimize and enhance its manufacturing capabilities to support its growing antibody drug conjugate (ADC) pipeline

  • January 2017

    Phase 1 study initiated in Japan evaluating safety and efficacy of U3-1402 in HER3-positive metastatic or unresectable breast cancer

  • 2016
    December 2016

    Daiichi Sankyo enters into strategic partnership with DarwinHealth to deploy a quantitative systems biology discovery platform to prioritize Daiichi Sankyo Cancer Enterprise compounds for development

  • November 2016

    DS-8201 granted Fast Track designation by the FDA for the treatment of HER2-positive unresectable and/or metastatic breast cancer in patients who have progressed after prior treatment with HER2-targeted therapies including ado-trastuzumab emtansine (T-DM1).

  • 2016
    October 2016

    Daiichi Sankyo enters into cross-licensing and collaboration agreement with ZymeWorks to develop a bi-specific antibody therapeutic

  • October 2016

    Daiichi Sankyo enters into a preclinical lung cancer research collaboration with Dana-Farber Cancer Institute

  • 2016
    October 2016

    Patritumab selected for inclusion in I-SPY2 TRIAL in breast cancer

  • October 2016

    Daiichi Sankyo enters into strategic collaboration with AgonOx, Inc. to develop undisclosed immune-oncology target

  • 2016
    October 2016

    Phase 3 QuANTUM-First study initiated examining safety and efficacy of quizartinib in newly-diagnosed FLT3-ITD-mutated AML

  • April 2016

    Antoine Yver, MD, MSc, appointed to Global Head, Oncology Research and Development, responsible for leading global research and development across the oncology therapeutic area

  • 2016
    March 2016

    Daiichi Sankyo announced 2025 Vision to become a "Global Pharma Innovator with a Competitive Advantage in Oncology"

  • November 2015

    Cobimetinib plus Zelboraf received FDA approval. Began co-promotion in the US with Genentech

  • 2015
    October 2015

    Pexidartinib granted Breakthrough Therapy Designation by the FDA for the treatment of tenosynovial giant cell tumor (TGCT)

  • August 2015

    Generic name for PLX3397, pexidartinib, recommended by the International Nonproprietary Names (INN) for Pharmaceutical Substances

  • 2015
    July 2015

    PLX3397 phase 1 extension data published in The New England Journal of Medicine

  • November 2014

    Acquired Ambit Biosciences to expand oncology pipeline

  • 2014
    February 2014

    PLX3397 granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA)

  • April 2012

    Launched Ranmark® (denosumbab) in Japan for treatment of bone complications stemming from multiple myeloma and bone metastases from solid tumors.

  • 2011
    August 2011

    Received FDA approval of Zelboraf® (vemurafenib). Co-promotion with Genentech began.

  • April 2011

    Acquired Plexxikon Inc. for oncology pipeline and drug development

  • 2009
    March 2009

    Quizartinib granted Orphan Drug Designation by the FDA (received by Ambit Biosciences prior to becoming part of Daiichi Sankyo)

  • May 2008

    Acquired U3 Pharma, a company with a pipeline of targeted antibody therapeutics for cancer

  • 1995

    Received approval of irinotecan in Japan, the first chemotherapy to demonstrate survival benefits in colorectal cancer

  • 1985

    Launched the first natural-type interferon beta preparation for brain tumor and skin cancer in Japan

  • 1977

    Launched Krestin® (Polysaccharide-K) in Japan to treat digestive, lung and breast cancer

Oncology more stories content

More Stories

Daiichi Sankyo Cancer Enterprise

The vision of Daiichi Sankyo Cancer Enterprise is to leverage our world-class, innovative science and push beyond traditional thinking in order to create meaningful treatments for patients with cancer.

read more ...

Oncology Helpful Resources All Links